285 related articles for article (PubMed ID: 14511362)
1. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity.
Takeda A; Homma S; Okamoto T; Kufe D; Ohno T
Eur J Clin Invest; 2003 Oct; 33(10):897-904. PubMed ID: 14511362
[TBL] [Abstract][Full Text] [Related]
2. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
3. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
4. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity.
Liu Y; Zhang W; Chan T; Saxena A; Xiang J
Leuk Res; 2002 Aug; 26(8):757-63. PubMed ID: 12191571
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
[TBL] [Abstract][Full Text] [Related]
6. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
7. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
8. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
Raje N; Hideshima T; Davies FE; Chauhan D; Treon SP; Young G; Tai YT; Avigan D; Gong J; Schlossman RL; Richardson P; Kufe DW; Anderson KC
Br J Haematol; 2004 May; 125(3):343-52. PubMed ID: 15086415
[TBL] [Abstract][Full Text] [Related]
9. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cell-mediated antitumor activity through the tumor necrosis factor-alpha pathway.
Nagasaki E; Takahara A; Koido S; Sagawa Y; Aiba K; Tajiri H; Yagita H; Homma S
J Immunother; 2010 Jun; 33(5):467-74. PubMed ID: 20463601
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.
Specht JM; Wang G; Do MT; Lam JS; Royal RE; Reeves ME; Rosenberg SA; Hwu P
J Exp Med; 1997 Oct; 186(8):1213-21. PubMed ID: 9334360
[TBL] [Abstract][Full Text] [Related]
12. Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo.
Rossowska J; Pajtasz-Piasecka E; Szyda A; Krawczenko A; Zietara N; Dus D
Oncol Rep; 2009 Jun; 21(6):1539-49. PubMed ID: 19424635
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
14. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.
Koido S; Hara E; Homma S; Torii A; Mitsunaga M; Yanagisawa S; Toyama Y; Kawahara H; Watanabe M; Yoshida S; Kobayashi S; Yanaga K; Fujise K; Tajiri H
J Immunol; 2007 Jan; 178(1):613-22. PubMed ID: 17182602
[TBL] [Abstract][Full Text] [Related]
15. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell fusion vaccines for cancer immunotherapy.
Rosenblatt J; Kufe D; Avigan D
Expert Opin Biol Ther; 2005 May; 5(5):703-15. PubMed ID: 15934845
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.
Shimizu K; Kuriyama H; Kjaergaard J; Lee W; Tanaka H; Shu S
J Immunother; 2004; 27(4):265-72. PubMed ID: 15235387
[TBL] [Abstract][Full Text] [Related]
18. Cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively induce dendritic cell maturation in vitro.
Hiraide A; Hiroishi K; Ishii S; Eguchi J; Imawari M
Anticancer Res; 2006; 26(1A):211-8. PubMed ID: 16475701
[TBL] [Abstract][Full Text] [Related]
19. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha.
Zhang W; Chen Z; Li F; Kamencic H; Juurlink B; Gordon JR; Xiang J
Immunology; 2003 Feb; 108(2):177-88. PubMed ID: 12562326
[TBL] [Abstract][Full Text] [Related]
20. In vitro hematopoiesis produces a distinct class of immature dendritic cells from spleen progenitors with limited T cell stimulation capacity.
Quah B; Ni K; O'Neill HC
Int Immunol; 2004 Apr; 16(4):567-77. PubMed ID: 15039387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
